Dachun Yang

Prof. Dachun Yang

School of Mathematical Sciences, Beijing Normal University, Beijing 100875, China
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2011 in JAMA
Verified
Journal Article
Open access
PDF file
DYDa Yang
Da Yang
SKSofia Khan
Sofia Khan
YSYan Sun
Yan Sun
KHKenneth Hess
Kenneth Hess
ISIlya Shmulevich
Ilya Shmulevich
WZWei Zhang
Wei Zhang
Increased surveillance of BRCA1/2 germ line mutation carriers is a generally accepted strategy for detecting early ovarian cancer. Women with BRCA1 mutations have a 39% to 54% cumulative lifetime risk of developing ovarian cancer and women with BRCA2 mutations have an 11% to 23% risk.1-3

1 April 2018 in Cancer Cell
Verified
Journal Article
Open access
ZWZehua Wang
Zehua Wang
BYBo Yang
Bo Yang
MZMin Zhang
Min Zhang
WGWeiwei Guo
Weiwei Guo
ZWZhiyuan Wu
Zhiyuan Wu
DYDa Yang
Da Yang
We characterized the epigenetic landscape of genes encoding long noncoding RNAs (lncRNAs) across 6,475 tumors and 455 cancer cell lines. In stark contrast to the CpG island hypermethylation phenotype in cancer, we observed a recurrent hypomethylation of 1,006 lncRNA genes in cancer, including EPIC1 (epigenetically-induced lncRNA1). Overexpression of EPIC1 is associated with poor prognosis in luminal B breast cancer patients and enhances tumor growth in vitro and in vivo. Mechanistically, EPIC1 promotes cell-cycle progression by interacting with MYC through EPIC1's 129-283 nt region. EPIC1 knockdown reduces the occupancy of MYC to its target genes (e.g., CDKN1A, CCNA2, CDC20, and CDC45). MYC depletion abolishes EPIC1's regulation of MYC target and luminal breast cancer tumorigenesis in vitro and in vivo.

10 September 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
CPChad V. Pecot
Chad V. Pecot
RRRajesha Rupaimoole
Rajesha Rupaimoole
DYDa Yang
Da Yang
RARehan Akbani
Rehan Akbani
CICristina Ivan
Cristina Ivan
ASAK Sood
AK Sood
The miR-200 family is well known to inhibit the epithelial–mesenchymal transition, suggesting it may therapeutically inhibit metastatic biology. However, conflicting reports regarding the role of miR-200 in suppressing or promoting metastasis in different cancer types have left unanswered questions. Here we demonstrate a difference in clinical outcome based on miR-200’s role in blocking tumour angiogenesis. We demonstrate that miR-200 inhibits angiogenesis through direct and indirect mechanisms by targeting interleukin-8 and CXCL1 secreted by the tumour endothelial and cancer cells. Using several experimental models, we demonstrate the therapeutic potential of miR-200 delivery in ovarian, lung, renal and basal-like breast cancers by inhibiting angiogenesis. Delivery of miR-200 members into the tumour endothelium resulted in marked reductions in metastasis and angiogenesis, and induced vascular normalization. The role of miR-200 in blocking cancer angiogenesis in a cancer-dependent context defines its utility as a potential therapeutic agent.

1 February 2013 in Cancer Cell
Verified
Journal Article
Closed access
DYDa Yang
Da Yang
YSYan Sun
Yan Sun
LHLimei Hu
Limei Hu
HZHong Zheng
Hong Zheng
PJPing Ji
Ping Ji
WZWei Zhang
Wei Zhang

1 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HZHong Zheng
Hong Zheng
LZLina Zhang
Lina Zhang
YZYanrui Zhao
Yanrui Zhao
DYDa Yang
Da Yang
FSFengju Song
Fengju Song
KCKexin Chen
Kexin Chen
Most (70%) epithelial ovarian cancers (EOCs) are diagnosed late. Non-invasive biomarkers that facilitate disease detection and predict outcome are needed. The microRNAs (miRNAs) represent a new class of biomarkers. This study was to identify and validate plasma miRNAs as biomarkers in EOC. We evaluated plasma samples of 360 EOC patients and 200 healthy controls from two institutions. All samples were grouped into screening, training and validation sets. We scanned the circulating plasma miRNAs by TaqMan low-density array in the screening set and identified/validated miRNA markers by real-time polymerase chain reaction assay in the training set. Receiver operating characteristic and logistic regression analyses established the diagnostic miRNA panel, which were confirmed in the validation sets. We found higher plasma miR-205 and lower let-7f expression in cases than in controls. MiR-205 and let-7f together provided high diagnostic accuracy for EOC, especially in patients with stage I disease. The combination of these two miRNAs and carbohydrate antigen-125 (CA-125) further improved the accuracy of detection. MiR-483-5p expression was elevated in stages III and IV compared with in stages I and II, which was consistent with its expression pattern in tumor tissues. Furthermore, lower levels of let-7f were predictive of poor prognosis in EOC patients. Our findings indicate that plasma miR-205 and let-7f are biomarkers for ovarian cancer detection that complement CA-125; let-7f may be predictive of ovarian cancer prognosis.

12 January 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KCKexin Chen
Kexin Chen
DYDa Yang
Da Yang
XLXiangchun Li
Xiangchun Li
BSBaocun Sun
Baocun Sun
FSFengju Song
Fengju Song
XHXishan Hao
Xishan Hao
Significance: We have identified a lethal subtype of gastric cancer (GC) that is characterized by high levels of clonal heterogeneity and TP53 (tumor protein P53) mutation. We have also uncovered key novel mutations in the targetable NRG1 (neuregulin-1) and ERBB4 (V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 4) ligand-receptor pair and identified BRCA2 (breast cancer 2, early onset) mutations as new genetic markers to predict better survival for GC. Our study represents a novel approach for GC personalized medicine and identified novel clinical actionable therapies for GC therapy.